Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation:

Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn’s disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780.

Highlights from this Publication

“In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who are likely to remain in remission and those who are likely to flare”.

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.

Health Canada License: 80726